Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives
Karolin Roemhild, Helena C. Besse, Wang Bi, Quim Peña, Qingxue Sun, Daiki Omata, Burcin Ozbakir, Clemens Bos, Hans W. Scheeren, Gert Storm, Josbert M. Metselaar, Haijun Yu, Ruth Knüchel‐Clarke, Fabian Kießling, Chrit Moonen, Roel Deckers, Yang Shi, Twan Lammers
Abstract
Background: Enzyme-activatable prodrugs are extensively employed in oncology and beyond. Because enzyme concentrations and their (sub)cellular compartmentalization are highly heterogeneous in different tumor types and patients, we propose ultrasound-directed enzyme-prodrug therapy (UDEPT) as a means to increase enzyme access and availability for prodrug activation locally.
Topics & Concepts
ProdrugDoxorubicinChemistryCytotoxicityEnzymeAdeptPharmacologyDrugBiochemistryIn vitroChemotherapyMedicineInternal medicineVirus-based gene therapy researchCancer Research and TreatmentsRNA Interference and Gene Delivery